US · ALVO
Alvotech
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Luxembourg 102
- Website
- alvotech.com
Price · as of 2024-12-31
$3.46
Market cap 1.24B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $62.02 | +1,692.49% |
| Intrinsic Value(DCF) | $4.46 | +28.9% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $112.78 | |||
| 2022 | $13.22 | $35.52 | $0.00 | $0.00 | $0.00 |
| 2023 | $15.60 | $26.08 | $0.00 | $0.00 | $0.00 |
| 2024 | $11.15 | $62.02 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Alvotech's (ALVO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $62.02
- Current price
- $3.46
- AI upside
- +1,692.49%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$4.46
+28.9% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALVO | Alvotech | $3.46 | 1.24B | +1,692% | +29% | — | — | -12.88 | -7.24 | 6.10 | -127.84 | — | -6.72 | 62.16% | 14.22% | -47.35% | 34.47% | 16.24% | -21.36% | -2.88 | 0.44 | 2.35 | 1.57 | -35.28 | -6420.00% | 43556.00% | -1807.00% | -9.84% | -1.22 | -68.51% | 0.00% | 0.00% | 0.00% | 59.25 | -14.04 | 8.43 | -0.85 |
| AMPH | Amphastar Pharmaceuticals… | $20.23 | 929.61M | +167% | -56% | -25% | -32% | — | 1.25 | 1.36 | 5.01 | — | 4.41 | 49.46% | 19.50% | 13.63% | 0.00% | 13.00% | 0.00% | 0.06 | 5.51 | 4.02 | 2.70 | -0.82 | -3366.00% | -165.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | — | 63.32% | 5.32 | — | 1.04 | 2.35 |
| BHVN | Biohaven Ltd. | $11.52 | 1.22B | — | — | — | — | -3.22 | 6.43 | — | -2.59 | -5.20 | 6.75 | 0.00% | — | — | -198.83% | -3466.81% | -150.03% | 0.09 | — | 3.49 | 3.17 | 0.07 | 6195.00% | — | 7519.00% | -21.53% | -3.78 | -2297.22% | 0.00% | 0.00% | 0.00% | -2.57 | -3.88 | — | 1.47 |
| COLL | Collegium Pharmaceutical,… | $41.67 | 1.32B | +93% | +451% | -64% | +46% | 20.98 | 4.37 | 1.69 | 4.41 | — | -2.57 | 59.35% | 23.01% | 8.05% | 23.70% | 14.73% | 3.79% | 2.70 | 2.18 | 1.57 | 1.36 | 1.47 | -699.00% | 2362.00% | 6111.00% | 24.84% | 0.75 | 39.58% | 0.00% | 0.00% | 17.45% | 9.73 | 5.33 | 2.24 | 1.51 |
| EVO | Evotec SE | $3.40 | 1.21B | +721% | -44% | — | — | -5.60 | 1.15 | 1.38 | -14.20 | -3.91 | 1.71 | 14.41% | -17.88% | -24.60% | -18.92% | -12.23% | -9.42% | 0.47 | -12.18 | 1.98 | 1.79 | -1.70 | 14348.00% | 199.00% | -3650.00% | -10.38% | 0.05 | -9.79% | 0.00% | 0.00% | 15.22% | -8.04 | -10.05 | 1.44 | 0.58 |
| HROW | Harrow Health, Inc. | $54.18 | 2.01B | +502% | +346% | — | — | -49.72 | 12.48 | 4.35 | 47.49 | — | -7.40 | 75.33% | 4.42% | -8.76% | -24.97% | 4.11% | -4.99% | 3.29 | 0.39 | 2.08 | 1.79 | 8.21 | -3467.00% | 5332.00% | -5906.00% | -7.00% | -0.24 | -28.36% | 0.00% | 0.00% | 0.00% | 119.11 | -17.26 | 5.26 | 1.98 |
| PAHC | Phibro Animal Health Corp… | $54.59 | 2.21B | +18% | +113% | -92% | -25% | 32.91 | 5.56 | 1.23 | 15.48 | 1.75 | 8.38 | 30.85% | 8.52% | 3.72% | 17.80% | 9.58% | 4.12% | 2.67 | 3.32 | 2.76 | 1.04 | 4.72 | 188333.00% | 2737.00% | -976.00% | 2.63% | 0.27 | 5.11% | 1.22% | 40.30% | 1.22% | 20.57 | 54.33 | 1.75 | 2.84 |
| PGNY | Progyny, Inc. | $17.69 | 1.53B | +175% | +6% | -48% | -30% | 25.63 | 2.91 | 1.16 | 12.09 | 182.64 | 3.06 | 23.63% | 6.62% | 4.54% | 12.48% | 23.59% | 8.67% | 0.05 | — | 2.73 | 2.62 | -0.88 | 1404.00% | 1040.00% | 1041.00% | 12.78% | 1.04 | 86.52% | 0.00% | 0.00% | 5.44% | 14.24 | 6.33 | 0.94 | 6.66 |
| SEM | Select Medical Holdings C… | $14.97 | 1.86B | +47% | -60% | — | +4% | 12.67 | 1.09 | 0.34 | 10.42 | — | -2.45 | 11.54% | 6.14% | 2.68% | 8.63% | 5.42% | 2.55% | 2.17 | 2.85 | 1.04 | 0.90 | 6.93 | -2892.00% | 512.00% | -2908.00% | 20.66% | 0.35 | 7.88% | 1.70% | 21.50% | 7.10% | 16.53 | 14.45 | 1.01 | 1.62 |
| TLRY | Tilray Brands, Inc. | $7.87 | 796.82M | -67% | -67% | — | — | -0.19 | 0.28 | 0.51 | -0.23 | -0.03 | 0.57 | 29.29% | -277.93% | -266.25% | -88.71% | -84.34% | -68.11% | 0.22 | -55.23 | 2.46 | 1.35 | -0.05 | 65170.00% | 484.00% | 11348.00% | -30.24% | -0.34 | -4.97% | 0.00% | 0.00% | 12.04% | -0.22 | -3.87 | 0.60 | -5.74 |
| UFPT | UFP Technologies, Inc. | $210.58 | 1.62B | -43% | +6% | -65% | +13% | 23.04 | 3.71 | 2.61 | 14.60 | 146.78 | 18.38 | 28.27% | 15.32% | 11.33% | 17.82% | 14.23% | 10.64% | 0.32 | 9.42 | 1.19 | 0.65 | 0.99 | 1570.00% | 1950.00% | 3871.00% | 5.02% | 0.58 | 14.70% | 0.00% | 0.00% | 4.92% | 18.29 | 21.39 | 2.80 | 5.53 |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
- CEO
- Vilhelm Robert Wessman
- Employees
- 1.01K
- Beta
- 0.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($4.46 ÷ $3.46) − 1 = +28.9% (DCF, example).